The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033
Market Overview and Growth
- Current Market Size: The hematocrit test devices market was valued at $4.35 billion in 2023.
- Projected Growth: Expected to reach $4.63 billion in 2024, with a compound annual growth rate (CAGR) of 6.4%.
- Historic Growth Drivers:
- Increased awareness of anemia and nutritional deficiencies.
- Rising incidence of chronic illnesses.
- Surge in government funding and population growth.
Future Growth Projections
- Forecasted Market Size: Anticipated to grow to $5.98 billion by 2028.
- Future CAGR: Expected to maintain a CAGR of 6.6%.
- Key Growth Factors:
- Rising prevalence of anemia and blood disorders.
- Increasing geriatric population and focus on health.
- Expanding need for cardiovascular diagnostic tools.
View More On The Hematocrit Test Devices Market Report 2024 – https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report
Impact of Blood Disorders
- Prevalence of Blood Disorders:
- Growing due to genetic factors, environmental pollution, and lifestyle changes.
- Blood disorders impact components like red blood cells, white blood cells, and platelets.
- Market Implications:
- Hematocrit test devices are crucial for measuring red blood cell volume in whole blood.
- Example: In January 2024, the American Cancer Society projected around 62,770 new leukemia cases in the U.S., boosting demand for hematocrit testing.
Major Market Players
- Leading Companies:
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Siemens Healthcare GmbH
- Innovative Developments: Companies are introducing advanced solutions and technologies, such as complete blood count (CBC) hematology analyzers.
Innovative Products in the Market
- CBC Hematology Analyzers:
- Functionality: Measure and analyze red and white blood cells, and platelets.
- Example: Mindray Medical’s BC-700 Series, featuring advanced SF Cube 3D technology for precise analysis.
- Technological Advancements:
- Integration of fluorescence and bi-angular laser scatter for detailed cell analysis.
Strategic Moves and Acquisitions
- Mars Incorporated and Heska Corporation:
- Acquisition: Mars acquired Heska Corporation in June 2023 for $1.3 billion.
- Impact: Expansion of Mars Petcare’s diagnostic capabilities and enhanced global pet healthcare solutions.
Market Segmentation
- By Product:
- Hematocrit Test Meter
- Hematocrit Test Analyzer
- Reagents and Consumables
- By Application:
- Anemia
- Polycythemia Vera
- Congenital Heart Diseases
- Other Applications
- By End-User:
- Hospitals and Ambulatory Surgical Centers
- Clinics
- Diagnostic and Pathology Labs
- Other End-Users
Regional Insights
- Current Leader: North America was the largest market in 2023.
- Future Growth: Asia-Pacific is anticipated to be the fastest-growing region in the forecast period.
Conclusion
The hematocrit test devices market is experiencing robust growth driven by increasing awareness of blood disorders, technological advancements, and strategic acquisitions. With a forecasted rise in market size and the introduction of innovative products, the industry is set for a promising future
Request A Sample Of The Global Hematocrit Test Devices Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15582&type=smp